PT-141 and libido: what the clinical data actually shows

What did @adamvanspanje actually say?

The core claim here is that PT-141 targets the brain rather than blood vessels, making it distinct from PDE5 inhibitors like sildenafil. The creator says it works on "melanocortin receptors in the brain linked to sexual function" and has been studied for erectile dysfunction and "hyperactive sexual desire disorder." They also note it is not TGA-approved in Australia. That's a reasonable summary of the drug's mechanism and regulatory status, delivered with appropriate caveats.

Worth noting: the creator correctly flags that PT-141 is not approved by Australia's TGA, and tells viewers to consult a healthcare provider. That kind of disclosure is increasingly rare in peptide content on TikTok, and it matters.

Does the science back this up?

Mostly, yes, though the picture is more complicated than a short video can convey. PT-141's central mechanism is reasonably well-established. It is a melanocortin receptor agonist, primarily acting on MC3R and MC4R receptors in the hypothalamus, which are involved in sexual arousal signaling. This is meaningfully different from how sildenafil works.

The FDA approved bremelanotide under the brand name Vyleesi in 2019, specifically for hypoactive sexual desire disorder (HSDD) in premenopausal women. That approval was based on two Phase 3 trials: the RECONNECT studies (Kingsberg et al., 2019, Obstetrics and Gynecology). Those trials showed statistically significant improvements in sexual desire and reductions in distress related to low desire. Effect sizes were modest but real.

For erectile dysfunction, the evidence is thinner. Early Phase 2 trials showed promise (Rosen et al., 2004, International Journal of Impotence Research), but PT-141 never received FDA approval for ED. The creator implies ongoing clinical exploration, which is accurate, but framing ED as an established studied indication without noting the lack of approval is a small but meaningful omission.

What did they get wrong (or right)?

The terminology slips are minor but worth flagging. The creator calls it "hyperactive sexual desire disorder," which is not a real diagnostic term. The correct condition studied is hypoactive sexual desire disorder (HSDD), meaning low desire, not excessive desire. That is the opposite of what the word "hyperactive" suggests, and it could genuinely confuse viewers about what this drug is actually approved to treat.

The mechanism description is largely accurate. Saying PT-141 "works on your brain" rather than the vascular system is a fair simplification. The creator gets credit for not overclaiming: no promises of guaranteed results, no dosing information, no claim that it cures anything. That restraint is appropriate given the regulatory and clinical reality.

One genuine gap: the video says nothing about the side effect profile. Nausea affects a significant portion of users in clinical trials, and transient increases in blood pressure were documented in the RECONNECT studies. That is not a trivial omission for a health-oriented video.

What should you actually know?

PT-141 has a real evidence base for HSDD in premenopausal women, grounded in FDA-reviewed Phase 3 data. Its use for erectile dysfunction or male sexual dysfunction more broadly is off-label and supported by earlier, smaller trials only. The compounded versions circulating in peptide clinics are not the same as Vyleesi, and there is no approved regulatory pathway for compounded bremelanotide in Australia.

The TGA has not approved PT-141 for any indication in Australia, which the creator correctly states. That means access is either through a Special Access Scheme application or, more commonly, through compounding pharmacies operating in a regulatory grey zone. If you are considering this, the conversation with your healthcare provider needs to include the source and quality of whatever you are being offered, not just whether it might work.

• Blood pressure effects are real: transient hypertension was reported in trials and is a contraindication concern for some patients.
• Nausea is the most common side effect reported in Phase 3 data, affecting roughly 40 percent of participants at the approved dose.
• The FDA-approved indication is HSDD in premenopausal women only. Other uses are off-label.